The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S. bladder cancer patient registry at the 2025 American Society of Clinical ...

Among patients with low-grade, intermediate-risk NMIBC, UGN-102 generated robust, durable responses in an analysis of the ...

The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S.

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, ...

New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and ...

Bladder cancer can be curable, and the likelihood of cure is higher if it is diagnosed at an early stage. Without treatment, bladder cancer does not go away on its own, and treatment is associated ...

Neuropathy, skin rash, and hyperglycemia following enfortumab vedotin treatment were associated with improved PFS in ...

She is also the chief medical officer of the lab consultancy firm Blood Associates, LLC. Bladder cancer occurs when cancerous cells form in the tissues of the bladder, the hollow organ in your ...

non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), today announced three poster presentations at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) to be held February ...

Rondo Therapeutics, a privately held biopharmaceutical immuno-oncology company pioneering the development of next-generation T cell-engaging bispecific antibodies for the treatment of solid tumors, ...

Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.